AN INTERVENTIONAL, OPEN-LABEL, RANDOMIZED, MULTICENTER PHASE 3 STUDY OF PF-07220060 PLUS LETROZOLE COMPARED TO CDK4/6 INHIBITOR PLUS LETROZOLE IN PARTICIPANTS OVER 18 YEARS OF AGE WITH HORMONE RECEPTOR (HR)-POSITIVE, HER2-NEGATIVE ADVANCED/METASTATIC BREAST CANCER WHO HAVE NOT RECEIVED ANY PRIOR SYSTEMIC ANTICANCER TREATMENT FOR ADVANCED/METASTATIC DISEASE (FOURLIGHT-3)
Latest Information Update: 21 Jan 2025
Price :
$35 *
At a glance
- Drugs Atirmociclib (Primary) ; Ribociclib (Primary) ; Abemaciclib; Letrozole; Palbociclib
- Indications Advanced breast cancer; HER2 negative breast cancer
- Focus Registrational; Therapeutic Use
- Acronyms FOURLIGHT-3
- Sponsors Pfizer
- 16 Jan 2025 Planned End Date changed from 20 Jan 2038 to 26 Dec 2037.
- 16 Jan 2025 Planned primary completion date changed from 24 Jan 2029 to 30 Dec 2028.
- 16 Jan 2025 Status changed from not yet recruiting to recruiting.